A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Hope S. Rugo, Kathryn J. Ruddy et al.|Breast Cancer Research and Treatment|2017Cited by 18
A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer.Scot Ebbinghaus, José Baselga, Joanne L. Blum et al.|Journal of Clinical Oncology|2011Cited by 5
Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancerJosé Baselga, HS Rugo, Serafín Morales et al.|Cancer Research|2013Cited by 3
A phase 2 study of ridaforolimus and dalotuzumab in estrogen receptor positive breast cancerJosé Baselga, Hope S. Rugo, Serafin M. Morales et al.|University of Southern Denmark Research Portal (University of Southern Denmark)|2013Cited by 0